Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys

• Published in: Vaccine Vol. 40; no. 31; pp. 4231 - 4241
• Main Authors: Hashimoto, Masayuki, Nagata, Noriyo, Homma, Tomoyuki, Maeda, Hiroki, Dohi, Keiji, Seki, Naomi M., Yoshihara, Ken, Iwata-Yoshikawa, Naoko, Shiwa-Sudo, Nozomi, Sakai, Yusuke, Shirakura, Masayuki, Kishida, Noriko, Arita, Tomoko, Suzuki, Yasushi, Watanabe, Shinji, Asanuma, Hideki, Sonoyama, Takuhiro, Suzuki, Tadaki, Omoto, Shinya, Hasegawa, Hideki
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 29.07.2022; Elsevier Limited; The Authors. Published by Elsevier Ltd
• Subjects: adjuvants; Allergy and Immunology; Animals; Antibodies; Antibodies, Neutralizing; Antibodies, Viral; Antigens; Cell-mediated immunity; Chromatography; Clinical trials; Coronavirus disease 2019; Coronaviruses; COVID-19; COVID-19 - prevention & control; COVID-19 - therapy; COVID-19 Serotherapy; COVID-19 vaccines; Cynomolgus monkeys; Dosage; dose response; Enzymes; genomics; humans; Immune response (humoral); Immunization; Immunization, Passive; Immunogenicity; Immunogenicity, Vaccine; Laboratories; Lung diseases; Lymphocytes T; Macaca fascicularis; messenger RNA; Monkeys; Neutralizing; pandemic; Pandemics; Proteins; Pseudoviridae; Recombinant protein vaccine; S-268019-b; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus; Squalene; throat; Vaccine efficacy; Vaccines; Viral diseases; Viral Vaccines; Viruses; Weight loss; United States > US; Japan; Cynomolgus monkeys; Severe acute respiratory syndrome coronavirus 2; Coronavirus disease 2019; Recombinant protein vaccine; S-268019-b

•A novel SARS-CoV-2 recombinant spike (S)-protein vaccine S-268019-b was developed.•S-268019-b induced antibodies against S-protein and its receptor binding domain.•Neutralizing antibody was induced against SARS-CoV-2 and pseudovirus variants.•S-268019-b demonstrated protective efficacy against SARS...